Recent Promotions

PKD2 Knockout HEK293 Cell Line

PKD2 Knockout HEK293 Cell Line
Cat.No.:

EDJ-KQ14778

Species:

Human

Cell Name:

HEK293

Gene:

PKD2

Gene ID:

5311

Size:

1×10⁶cells

PKD2 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
Cat.No. EDJ-KQ14778
Product Name PKD2 Knockout Cell Line (HEK293)
Cell Line HEK293
Cellosaurus ID CVCL_0045
Cell Line Synonyms Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293
Gene
NCBI Gene ID
Gene Synonyms APKD2|PC2|PKD4|Pc-2|TRPP2
Summary
This gene encodes a member of the polycystin protein family. The encoded protein is a multi-pass membrane protein that functions as a calcium permeable cation channel, and is involved in calcium transport and calcium signaling in renal epithelial cells. This protein interacts with polycystin 1, and they may be partners in a common signaling cascade involved in tubular morphogenesis. Mutations in this gene are associated with autosomal dominant polycystic kidney disease type 2. [provided by RefSeq, Mar 2011]
Associated Diseases Non-tumor
Morphology Adherent
Passage Ratio 1/5,2days
Complete Culture Medium DMEM + 10% FBS
Freezing Medium 95% Complete culture medium+ 5% DMSO
QC Indels validated by Sanger sequencing; sterility confirmed via microbial testing.
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
LociSTR Info (Sample Cell)
Sample Cell Line: HEK293
STR Info (Cell bank)
Cell Line: HEK293
Allele1Allele2Allele1Allele2
Amelogenin X X
CSF1P0 12 11 12
D2S1338 19 19
D3S1358 15 17 15 17
D5S818 8 8 9
D7S820 11 12 11 12
D8S1179 12 14 12 14
D13S317 12 14 12 14
D16S539 9 13 9 13
D18S51 17 18 17 18
D19S433 15 18 15 18
D21S11 28 30.2 28 30.2
FGA 23 23
Penta D 9 10 9 10
Penta E 7 15 7 15
TH01 7 9.3 7 9.3
TPOX 11 11
vWA 16 19 16 19
D6S1043 11 11
D12S391 19 21 11 15
D2S441 11 15 11 15
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.

Research Publications

IF=3.9
Scientific reports
Recent advances in induced pluripotent stem cells (iPSCs), genome editing technologies and 3D organoid model systems highlight opportunities to develop new in vitro human disease models to serve drug discovery programs. An ideal disease model would accurately recapitulate the relevant disease phenotype and provide a scalable platform for drug and genetic screening studies. Kidney organoids offer a high cellular complexity that may provide greater insights than conventional single-cell type cell culture models. However, genetic manipulation of the kidney organoids requires prior generation of genetically modified clonal lines, which is a time and labor consuming procedure. Here, we present a methodology for direct differentiation of the CRISPR-targeted cell pools, using a doxycycline-inducible Cas9 expressing hiPSC line for high efficiency editing to eliminate the laborious clonal line generation steps. We demonstrate the versatile use of genetically engineered kidney organoids by targeting the autosomal dominant polycystic kidney disease (ADPKD) genes: PKD1 and PKD2. Direct differentiation of the respective knockout pool populations into kidney organoids resulted in the formation of cyst-like structures in the tubular compartment. Our findings demonstrated that we can achieve > 80% editing efficiency in the iPSC pool population which resulted in a reliable 3D organoid model of ADPKD. The described methodology may provide a platform for rapid target validation in the context of disease modeling.
IF=3.9
The Journal of biological chemistry
Mutations in the co-chaperone DNAJB11 have been shown to cause polycystic kidney disease. The molecular mechanism underlying DNAJB11-related kidney disease involves impaired processing of Polycystin-1 (PC1), the protein most commonly mutated in autosomal dominant polycystic kidney disease (ADPKD). Chaperones are known to form multiprotein complexes to facilitate folding and processing of client proteins. Yet, it is unknown whether DNAJB11 forms complexes with other proteins that are required for PC1 processing. In this study, we perform an unbiased interaction proteomics screen for DNAJB11-interacting proteins. We identify two highly homologous proteins, SDF2 and SDF2L1, as strong interaction partners of DNAJB11. Using newly established knockout cell lines, we demonstrate a reciprocal interdependence of DNAJB11 and SDF2/SDF2L1 protein abundance. Furthermore, we show that concomitant loss of SDF2 and SDF2L1 impairs PC1 processing, mimicking the biochemical phenotype caused by loss of DNAJB11. Using a combination of knockout cell lines and reexpression of the respective members of the DNAJB11 protein complex, we show that SDF2 or SDF2L1 are elementary subunits of the DNAJB11 complex required for normal PC1 processing.
This KO model may be useful for: - Investigating the role of PKD2 in polycystin-1 processing and maturation pathways - Functional validation of co-factors such as SDF2, SDF2L1, and DNAJB11 in autosomal dominant polycystic kidney disease (ADPKD) - Target validation and gene-editing studies in kidney disease models using Cas9-inducible systems - Drug screening and phenotypic assays for ADPKD-related cellular mechanisms - Mechanistic studies of ciliary signaling and calcium homeostasis in renal epithelial cells

Recommended Accessories

Related Products

Flash CRISPR Knockout Kit(Universal Version)Flash CRISPR Knockout Kit(Universal Version)
Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)Flash-Pro CRISPR KO Kit (For Organoids / Stem Cells)

Related Services

Knockout Cell LineKnockout Cell Line
Contact Us
*
*
*
How did you hear about us: